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Abstract
Purpose—Pre-operative (pre-op) chemoradiation therapy (CRT) improves local control and
reduces toxicity more than post-operative (post-op) CRT for the treatment of stages II/III rectal
cancer, but studies suggest many patients still receive post-op CRT. We examined patient beliefs,
and clinical and provider characteristics associated with receipt of recommended therapy.
Methods—We identified stage II/III rectal cancer patients who had primary site resection and
CRT among subjects in the Cancer Care Outcomes Research and Surveillance Consortium, a
population- and health system-based prospective cohort of newly diagnosed colorectal cancer
patients from 2003 to 2005. Patient surveys and abstracted medical records were used to construct
variables and determine sequence of CRT and surgery. Logistic regression was used to model the
association between predictors and receipt of pre-op CRT.
Results—Of the 201 patients, 66% received pre-op and 34% received post-op CRT. Those
visiting a medical oncologist and/or radiation oncologist prior to a surgeon had a 96% (95% CI,
92% to 100%) predicted probability of receiving pre-op CRT, compared to 48% (95% CI, 41% to
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55%) for those visiting a surgeon first. Among those visiting a surgeon first, documentation of
recommended staging procedures was associated with receiving pre-op CRT.
Conclusion—Sequence of provider visits and documentation of recommended staging
procedures were important predictors of receiving pre-op CRT. Initial multidisciplinary evaluation
led to better adherence to CRT guidelines. Further evaluation of provider characteristics, referral
patterns and related health system processes should be undertaken to inform targeted interventions
to reduce variation from recommended care.
Background
Colorectal cancer is the third leading cause of cancer deaths in the United States and was
associated with 51,370 deaths in 2010. Of 141,210 incident cases of colorectal cancer in
2011, 28% (39,510) were rectal.1 Compared to colon cancer, rectal cancer is associated with
increased risk of local recurrence and worse overall prognosis.2–5 Rectal cancer therapies
are also associated with higher morbidity, including problems with bowel function, urinary
and fecal continence, and sexual functioning.
The standard of care for stages II and III rectal cancer previously involved surgical resection
and post-operative (post-op) chemoradiation therapy (CRT). However, more recent studies
have shown several advantages to pre-operative (pre-op) CRT including improved local
control and reduction in toxicity.6–8 Some evidence suggests that pre-op CRT is also
associated with more sphincter preserving surgeries than post-op CRT.7 Consequently,
national guidelines recommend pre-op CRT for all patients with stage II/III rectal cancer.9
While pre-op CRT is considered the standard of care, many patients still receive post-op
CRT. Previous studies of stage II/III rectal cancer patients using SEER or other registry data
found rates of pre-op radiation therapy (RT) were increasing as rates of post-op RT were
decreasing, but substantial treatment variability remained. Among patients diagnosed with
rectal cancer between 2003 and 2005 who received both surgery and RT, 60% received pre-
op RT and 40% received post-op RT.10–12 Studies based on SEER data found patients
receiving pre-op RT were younger and more likely to be male compared to those receiving
post-op RT, and demonstrated geographic variation.10–11 More recent SEER Stat data from
2007 and 2008 indicates that 28% of stage II/III rectal cancer patients who received CRT for
rectal cancer still received CRT post-operatively.13
SEER has limited data on potential explanatory variables for this variation. Using data from
the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS), the primary
objectives of this study were to characterize in more detail the differences between patients
who received pre-op CRT and those who received post-op CRT, and the attributes of
physicians who practice in any of the participating CanCORS facilities. While the
CanCORS cohort spanned a transitional time period from late 2003 through 2005 during
which the proportion of stage II/III rectal cancer patients receiving pre-op CRT was
approximately 60%, relatively little has changed in recent years with just over 70%
receiving pre-op CRT in 2008. Factors associated with receipt of CRT during the CanCORS
study period are therefore still very relevant today. In addition, there was at least some
awareness of changing guidelines by the beginning of the CanCORS study period, as the
National Comprehensive Cancer Network (NCCN) Guidelines incorporated pre-op CRT
into their recommended course of treatment in 200314 and multiple trials had begun
reporting results at national conferences and in journals in 2003.15–19 We examined patient
beliefs, and clinical and provider characteristics associated with receipt of recommended
therapy.
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CanCORS is a population and health-system based cohort study including approximately
4,713 adults with newly diagnosed colorectal cancer recruited between 2003 and 2005 from
geographically diverse populations and healthcare systems. It contains detailed information
on the acute treatment phase, including surgery, chemotherapy and RT regimens, and
information on the clinical and patient-reported outcomes experienced by the patient.20–22
CanCORS participants with stage II or III rectal adenocarcinoma who had primary site
resection, RT and chemotherapy initiated within 180 days of surgery, no recurrence within
180 days of diagnosis and no history of prior cancer were studied. Medical record
information was used to assign American Joint Committee on Cancer collaborative stage.23
Surgery, RT and chemotherapy information was extracted from medical records, which
covered 30 days prior to and at least 15 months after diagnosis. Medical record information
was reviewed to determine dates of service, radiation dose ( (i) <4500 cGy, (ii) 4500 – 5040
cGy, and (iii) ≥5040 cGy), surgical approach (abdominal perineal resection (APR), lower
anterior resection (LAR), other), chemotherapy regimens [(i) 5-fluorouracil (5-FU),
leucovorin and/or capecitabine with no other agents; (ii) regimens including agents other
than 5-FU, leucovorin or capecitabine, such as irinotecan, oxaliplatin or bevacizumab; or
(iii) unspecified], Adult Comorbidity Evaluation – 27 (ACE-27) comorbidity indicators,24
documentation of recommended staging procedures [computed tomography (CT) of the
abdomen and chest, and magnetic resonance imaging (MRI) of the pelvis or endorectal
ultrasound (EUS)], and tumor size and location.
Sequence of visits to the medical oncologist and/or radiation oncologist and the surgeon was
also captured. Medical record abstractors were instructed to record all dates associated with
patient-provider contacts. For analytic purposes, new consultations, clinical office follow-up
notes, emergency department/urgent care clinic visits, radiation treatment visits (with
provider contact), chemotherapy, transfusion, or other intravenous medication
administration (with physician contact) and patient-to-provider phone calls were considered
to be visits. If no visit to a medical oncologist, a radiation oncologist or a surgeon was
recorded prior to the initiation of their respective therapies/procedures, the first date of
treatment was used as the first visit date for that corresponding provider type.
Sociodemographic information (age, sex, education, income, race, income), health insurance
status, patient beliefs and treatment preferences were obtained from self-reported baseline
patient surveys.21
Data Analysis
Univariate statistics, Chi-square test, Fisher’s exact test and Wilcoxon rank sum test were
used to compare the pre-op and post-op CRT groups on key variables. Logistic regression
was used to model the association between predictors and receipt of pre-op CRT, and obtain
both covariate-adjusted predicted proportions and predicted marginal counts of subjects
receiving pre-op CRT.25
The set of candidate predictive variables included age, gender, race, income, health
insurance (none vs. covered by at least one insurer/payer), education (no 4-year college vs.
at least some 4-year college), marital status (lives alone vs. married or lives with partner),
stage of cancer (II vs. III), CanCORS research site affiliation, sequence of physician visits
(surgeon first vs. medical and/or radiation oncologist first), documentation of staging
procedures, comorbidities (ACE-27 categories and individual conditions), tumor size and
location and patient treatment beliefs and preferences. Age and cancer stage were considered
key predictors and were not candidates for removal in a backward variable selection
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procedure, used to eliminate non-informative or redundant predictors. Sensitivity analyses
limited to patients with documented provider visits prior to treatment were performed.
A descriptive analysis of a random sample of surgeons, radiation oncologists and medical
oncologists who cared for CanCORS patients in the previous 12 months, including those
with colorectal cancer was also performed. Methods and instruments used in relation to the
CanCORS physician survey have been previously described.26
Results
Of the 311 CanCORS patients with stages II/III rectal adenocarcinoma and primary site
resection, 201 met all inclusion criteria (Figure 1). The characteristics of pre-op and post-op
CRT groups are described in Table 1. Higher proportions of those receiving pre-op CRT had
stage II disease and documentation of a pre-treatment MRI of the pelvis or rectal EUS and
CT of the chest. Those receiving post-op CRT had a higher proportion of tumors located at
the rectosigmoid junction, significantly larger tumors and angina/coronary artery disease.
There were no differences in demographics, such as age, gender, ethnicity, marital status,
education, income or insurance status, between groups.
The two groups differed significantly in the sequence of their provider visits. Forty-four
percent of those who received pre-op CRT visited a medical or radiation oncologist prior to
visiting a surgeon, whereas only 4% of those who received post-op CRT visited a medical or
radiation oncologist prior to visiting a surgeon, and 71% of the pre-op group visited a
surgeon and a medical or radiation oncologist prior to receiving any treatment compared to
13% of the post-op group.
As illustrated in Table 2, there were no significant differences between those who received
pre-op and post-op CRT in their preferred decision-making roles and beliefs related to RT,
surgery and chemotherapy, with two exceptions. A higher proportion of people who
received post-op CRT reported that RT would very likely or somewhat likely cure their
cancer. Conversely, a higher proportion of people who received pre-op CRT reported that
the RT would very likely or somewhat likely help with the symptoms they were having from
their cancer. Almost all respondents reported receiving high quality care from their
providers, with no differences by pre-op/post-op CRT status.
The adjusted probabilities of receiving pre-op CRT based on the characteristics of 201
patients in the final logistic model are displayed in Table 3. Subjects visiting a medical or
radiation oncologist prior to a surgeon had a 96% (95% CI, 92% to 100%) adjusted
probability of receiving pre-op CRT, whereas those visiting a surgeon first had a 48% (95%
CI, 41% to 55%) adjusted probability of receiving CRT. In addition, those who visited a
surgeon and a medical or radiation oncologist prior to any treatment had a 92% (95% CI,
87% to 97%) adjusted probability of receiving pre-op CRT, whereas those visiting only a
surgeon or a medical or radiation oncologist had a 32% (95% CI, 25% to 39%) adjusted
probability. No other patient characteristics remained significant in this model. Sensitivity
analyses limited to those with documented visits prior to treatment yielded very similar
results.
Since there was virtually no variation in CRT-surgery sequence among those who visited a
medical or radiation oncologist before a surgeon, but there was substantial variation among
those who visited a surgeon first, we created a separate logistic model for those 140 subjects
(Table 3). Among patients who saw a surgeon first, those who had documentation of a
pelvic MRI or EUS had a 74% (95% CI, 62% to 85%) adjusted probability of receiving pre-
op CRT, whereas the others had a 40% (95% CI, 30% to 50%) adjusted probability. Also,
those who had a documentation of a chest CT were more likely to have pre-op CRT.
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We reported survey results from surgeons, radiation oncologists and medical oncologists
who had cared for at least one CanCORS colorectal cancer (CRC) patient in the previous 12
months in Table 4. The most notable differences among these provider types were related to
the volume of CRC patients treated in the last month and the percentage reporting weekly
attendance at multidisciplinary meetings (e.g. tumor boards). Medical oncologists, radiation
oncologists and surgeons reported seeing a median of 10, 3 and 3 CRC patients in the last
month respectively, and 67%, 82% and 36% reported attending weekly multidisciplinary
meetings, respectively.
A description of treatment characteristics and their association with the sequence of CRT
and surgery is provided in Table 5. Those who received pre-op CRT were more likely to
have been given the standard total radiation therapy dose of 4500–5040 cGy and to have had
an APR approach, whereas the post-op CRT patients were more likely to have been given a
dose greater than 5040 cGy and have had a LAR approach. There were no significant
differences in chemotherapy regimens or number of days between initiation of CRT and
surgery.
Discussion
Consistent with previous evaluations of SEER data, we found 34% of patients with stage II/
III rectal cancer received post-op CRT. Unlike those studies, we did not find significant
differences in use of pre- vs. post-op CRT related to patient gender or age.10–11 Rather, our
findings suggest provider characteristics play a larger role in determining sequencing of
rectal cancer therapies than patient characteristics. After accounting for multiple factors,
nearly all subjects visiting a medical and/or radiation oncologist prior to visiting a surgeon
received pre-op CRT, whereas only 48% of those who visited a surgeon first received pre-op
CRT. Similar to our study, Luo (2006) reported that referral to a medical oncologist was the
most important factor associated with receipt of chemotherapy among older patients with
stage III colon cancer.27 However, no other studies have reported on the significance of the
visit sequence of surgeons and oncologists. It is possible that the visit sequence variables
available in CanCORS, which are not available in SEER, are far stronger predictor variables
than age and gender and explain the difference in findings among the studies.
Among those who visited a surgeon first, we found patients who had a pelvic MRI or EUS
and a chest CT were more likely to receive pre-op CRT. It is possible that access to EUS
was an issue for some patients, and that pelvic MRI had not been adopted by some providers
as an acceptable alternative, so the decision was made to perform surgery first. In addition,
receipt of these recommended staging procedures may be a proxy measure capturing quality
care provided by physicians experienced in treating patients with rectal cancer. While
characteristics of specific providers treating patients in our study were not available, we
evaluated the overall CanCORS colorectal cancer provider population. Surgeon respondents
were less likely than medical or radiation oncologists to report attendance at
multidisciplinary meetings to discuss cancer care (e.g. tumor boards) at least weekly. This
may indicate that some surgeons do not treat a high enough volume of rectal cancer patients
to be familiar with changing guidelines for care. We found the median number of CRC
patients evaluated in the previous month by the surgeon respondents was three, and the
median number of colon or rectal resections per month was two; fewer than half of those are
likely to be rectal resections.
Another analysis of CanCORS data found those surgeons identifying themselves as
colorectal surgeons or surgical oncologists (16%) were more likely to report high volumes
of colorectal cancer resections, and high volume surgeons were more likely to report
collaborative decision-making with other physicians on adjuvant therapies.28 Several studies
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have previously shown that surgeon specialty influences patient management in colorectal
cancer care. One study showed patients treated by colorectal surgeons were far more likely
to receive pre-op CRT than those treated by general surgeons (91% vs. 17%).29 A survey of
surgeons in Florida also found that general surgeons were significantly less likely than
colorectal surgeons or surgical oncologists to refer their patients for pre-op CRT, and less
likely to report adherence to NCCN recommended staging guidelines.30 A survey of
Canadian surgeons yielded similar results regarding recommended staging procedures.31
Other studies have linked specialty training and/or surgeon volume of colorectal cancer
patients treated annually with receipt of recommended treatment and better outcomes.32–34
Interestingly, in contrast to other GI malignancies, there has been no evidence of shift
toward high volume centers for rectal cancer cases.35–36
Our findings suggest that patients’ beliefs about the effects of radiation treatment are
influenced by the order in which treatments are recommended to them. In unadjusted
analyses, a higher proportion of people who received post-op CRT reported belief that RT
would very likely or somewhat likely cure their cancer whereas a higher proportion of
patients who received post-op CRT believed RT would not be likely to help with their
symptoms. That seeing a surgeon first removed this association in multivariate models
suggests that it was the sequence of visits that mediated the difference between pre-op and
post-op patient beliefs. The phrasing of the survey items to elicit beliefs after discussing
treatment with their physicians (i.e. “after talking with your doctors about radiation therapy,
how likely did you think it was that….”) further supports a direct influence of physician visit
sequence and not merely selection of patients who innately believe in the curability of
cancer to seek out surgeons first. It is noteworthy that nearly all subjects, regardless of
treatment sequence, rated their quality of care good to excellent for surgery, RT and
chemotherapy.
With respect to subsequent treatment regimen characteristics, a higher proportion of those
who underwent pre-op CRT received standard doses of radiation (4500 to 5040 cGy in 25 to
28 fractions regardless of the sequence of RT and surgery)9, whereas a higher proportion of
those who underwent post-op CRT received a higher dose of radiation (>5040 cGy). We
hypothesized that among patients who underwent surgery as first line treatment, those who
had positive surgical margins may have been given a higher radiation dose post-operatively.
However, there were only two post-op CRT subjects with documented positive margins, and
only one of those had a higher than normal dose of radiation. Since the post-op surgical bed
is associated with more damage to blood vessels and diminished blood flow and oxygen
supply, some radiation oncologists may use a higher dose to achieve better local control.37
Patients who received pre-op CRT were more likely to have open APR approach, whereas
those who received post-op CRT were more likely to have a LAR approach, which is not
consistent with results of other studies of pre-op and post-op CRT.7, 38–39 It is possible that
surgeons are more likely to refer patients with low rectal tumors for pre-op CRT in attempts
to reduce the tumor size sufficiently enough to allow for the sphincter-sparing LAR
approach. Pre-op CRT may not be able to always achieve this objective in many instances
and the APR approach may still be necessary.
This study has some potential limitations. Staging was based upon the highest level of
pathologic and clinical information available in the medical record. Thus, it is possible that
some of the patients receiving post-op CRT could have been clinically staged as stage I and
consequently received first line surgery, and were then found to have stage II/III rectal
cancer during surgery and received post-op CRT. However, those who received post-op
CRT were less likely to have documentation of a chest CT or pelvic MRI/EUS in their
medical record as part of clinical staging. NCCN guidelines indicate that all rectal patients
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should have pelvic MRI or EUS, and a CT of the chest, abdomen and pelvis to rule out
metastases to the liver and lung.9, 40 Thus, some patients may have failed to receive the
recommended treatment for stage II/III rectal cancer due to inaccurate staging.
Some patients with rectal cancer present emergently with bleeding or obstructing tumors. As
a result, it is reasonable to expect that a small portion of patients may have initial surgery for
symptom control. Still, even among cases of bleeding or obstruction, symptoms can often be
controlled with a diverting ostomy and CRT, so this does not justify the large differences in
rates of pre-op CRT.
In conclusion, a substantial proportion of patients with stages II/III rectal cancer received
post-op CRT despite compelling evidence supporting pre-op CRT. Receipt of pre-op CRT
was associated with visits to medical or radiation oncologists prior to surgeons and visits to
multiple provider types prior to initiation of treatment. The increased participation of
oncologists (compared to surgeons) in multidisciplinary team conferences, which have been
shown to improve processes and outcomes of care for colorectal cancer patients,41 is a
potential driver of the observed association and an ideal target for national quality
improvement initiatives. Pre-op CRT was also associated with receipt of recommended
staging procedures among subjects visiting a surgeon first. It is also possible that the
decision to perform post-op CRT may have been related to patient preference, lack of access
to recommended staging procedures or other logistic factors that created justifiable
circumstances. Consequently, further evaluation of patient treatment preferences, provider
characteristics, presence of multi-disciplinary treatment planning, access/availability of
staging procedures, referral patterns and health system processes that determine treatment
should be undertaken to understand variation from recommended care and design targeted
interventions to improve quality of care.
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Flowchart of study participants.
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Table 1
Characteristics of patients with stages II or III rectal cancer by chemoradiation therapy (CRT)—surgery
sequence status (pre-operative: pre-op; post-operative: post-op)





Research site affiliation 0.69
   Cancer Research Network (Health Maintenance Organization population) 22% 26%
   Veterans Affairs Health Care System 18% 15%
   Population-based Registry 60% 59%
Female gender 32% 34% 0.83
Lives alone 39% 35% 0.60
Ethnicity
White 60% 59% 0.96
African American 14% 15%




     <55 36% 37% 0.72
      55–64 33% 28%
      >=65 31% 35%
Stage III 42% 57% 0.04
Comorbidities‡ (ACE-27 categories & selected conditions)
   None 38% 38%
   Mild 38% 38%
   Moderate 17% 16%
   Severe 8% 7% 0.99
   Hypertension 32% 38% 0.35
   Angina/Coronary Artery Disease 8% 19% 0.02
   Arrhythmias 4% 0% 0.17
   Peripheral Artery disease 5% 3% 0.45
   Hepatic disease 4% 1% 0.37
   Obesity 7% 10% 0.38
   Respiratory 7% 9% 0.60
   Stomach/intestine 8% 4% 0.31
   Alcohol abuse 29% 18% 0.07
   Psychiatric disease 7% 7% 1.00
Staging Procedures
   Computed Tomography (CT)-abdomen/pelvis 88% 78% 0.06
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   Computed Tomography (CT)--chest 29% 13% 0.01
   Magnetic Resonance Imaging (MRI)--pelvis or Endorectal Ultrasound (EUS) 49% 25% <0.01
Median tumor size (interquartile range) in mm (N=144) 40 (25,50) 50 (35,60) 0.03
Tumor located at rectosigmoid junction (vs. rectum NOS) (N=199) 11% 27% <0.01
Visited a medical or radiation oncologist before a surgeon 44% 4% <0.01
Visited a medical or radiation oncologist and a surgeon prior to initiation of treatment 71% 13% <0.01
*
Total subjects=201 unless otherwise specified.
†
p values calculated based on Chi-square, Fisher’s exact or Wilcoxon rank sum tests as appropriate.
‡
Comorbidities displayed if at least 5 people in one group had documentation of the condition, and were categorized according to the Adult
Comorbidity Evaluation – 27 (ACE-27) indicators.
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Table 4
Characteristics of physicians practicing in participating CanCORS hospitals/facilities who cared for patients










Number of CRC patients treated/evaluated in past month (median) 3 10 3
Hospital/practice is part of a Community Clinical Oncology Program 40% 32% 31%
Practice at a National Cancer Institute-designated cancer center 23% 22% 29%
In practice affiliated with a National Comprehensive Cancer Network 22% 22% 25%
Board certified 94% 84% 90%
Involved in teaching medical students/residents 38% 53% 53%
Attend multidisciplinary meeting to discuss cancer care (e.g. tumor boards) at least weekly 82% 67% 36%
Do not attend multidisciplinary meeting to discuss cancer care 0% 2% 5%
Multidisciplinary meetings involve:
 A pretreatment planning function 86% 77% 73%
   Includes evaluation/review of treatment decisions already made 92% 86% 85%
 Reviews all participants’ cases 38% 41% 41%
 Reviews only challenging, unusual or controversial cases 58% 61% 50%
 Reviews a variety of cancer cases 91% 83% 82%
 Serves as a teaching session only, without review of cases 11% 14% 9%
*
These are not necessarily the physicians who cared for the rectal cancer population in this study. Rather, the sampling frame included providers
who cared for patients in the overall CanCORS initiative.
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Table 5







   Abdominal perineal resection 41% 25% 0.03
   Lower anterior resection 58% 72%
   Other 1% 3%
Positive margins documented 4% 3% 1.00
Median number of days (interquartile range) between
initiation of radiation & surgery 88 (78,101) 82 (49,108) 0.14
Chemotherapy regimen
   5FU/leucovorin or capecitabine 73% 75% 0.20
   Regimens including other agents* 23% 25%
   Unspecified 5% 0%
Radiation Therapy total dose (cGy) category (N=185)
   <4500 6% 6% <0.01
   ≥4500 & ≤ 5040 87% 59%
   >5040 7% 35%
   Missing dose information N=11 N=5
*
Other agents predominantly include Irinotecan, Oxaliplatin and Bevacizumab
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